Golder FJ. Spinal NMDA receptor activation is necessary for de novo, but not the maintenance of, A2a receptor-mediated phrenic motor facilitation. J Appl Physiol 107: 217-223, 2009. First published April 30, 2009 doi:10.1152/japplphysiol.00183.2009.-Adenosine 2a (A2a) receptor agonists elicit persistent increases in phrenic nerve activity by transactivating the neurotrophin receptor, TrkB, near phrenic motoneurons. Our working model proposes that A2a receptormediated TrkB receptor activation strengthens glutamatergic synapses onto phrenic motoneurons. Activation of glutamate N-methyl Daspartate (NMDA) receptors has been implicated in other models of phrenic motor plasticity. Thus we hypothesized that NMDA receptor activation also would contribute to A2a receptor-mediated phrenic motor facilitation. Adult male Sprague-Dawley rats were anesthetized with urethane, mechanically ventilated, neuromuscularly paralyzed, and bilaterally vagotomized. The A2a receptor agonist CGS-21680 and the NMDA receptor-channel blocker MK-801 were administered intrathecally over the C4 spinal segment. Phrenic nerve activity was recorded before, during, and after drug administration. MK-801 (concentration range 0.1, 1.0, 10.0, and 100 M) was administered 30 min before CGS-21680 (50 M). MK-801 dose-dependently blocked A2a receptor-mediated phrenic motor facilitation. When administered at 60 min post-CGS-21680, MK-801 prevented further increases in phrenic nerve activity compared with the CGS-21680 alone (CGS-21680 alone at 120 min: 114 Ϯ 19%; CGS-21680 and MK-801 at 60 min post-CGS-21680: 61 Ϯ 11%, above baseline, P Ͻ 0.05) but did not return phrenic motor output to baseline values. Our data suggest that NMDA receptor activation is necessary for de novo A2a receptormediated phrenic motor facilitation and that the maintenance of preexisting phrenic motor facilitation does not involve NMDA receptor-dependent mechanisms.
THE NEURAL ELEMENTS that control breathing must be adaptable to meet the physiological needs of an individual. Adaptation may be in the short term, such as modulation, or long term, such as neuroplasticity (25) . Potential sites of neuroplasticity include neurons responsible for rhythm generation (16) and pattern formation (27) , and respiratory motoneurons, such as phrenic motoneurons (20) . Models of respiratory motoneuron plasticity include intermittent hypoxia-induced phrenic longterm facilitation (LTF) (24) , the crossed phrenic phenomenon (14) , and A2a receptor-mediated phrenic motor facilitation (11) . Understanding the mechanisms contributing to phrenic motor plasticity may identify novel approaches to improve respiratory function in people with respiratory motor insufficiencies, such as occur after spinal cord injury (SCI).
Long-term increases in phrenic motor output may involve strengthening of excitatory connections to phrenic motoneurons. In spinal motoneurons, glutamate conveys the majority of fast excitatory synaptic transmission via the ␣-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) ionotropic receptor, and modulates synaptic strength in the short term and long term via N-methyl-D-aspartate (NMDA) receptors (35) . In the rat phrenic motor nucleus, NMDA receptors also contribute to fast excitatory synaptic transmission (6) . Thus phrenic motoneuron NMDA receptors may express synaptic plasticity (i.e., as a potentiated ion channel) and regulate synaptic plasticity within the same neuron. Indeed, NMDA receptors have been implicated in many models of synaptic plasticity (34, 36, 38, 39) , including phrenic LTF (23) .
Phrenic LTF is a form of serotonin-dependent spinal synaptic plasticity expressed as a progressive increase in phrenic motor output after exposing anesthetized rats to intermittent hypoxia (8) . Phrenic LTF requires new synthesis of brainderived neurotrophic factor (BDNF) and subsequent activation of the tropomyosin-related kinase type B (TrkB) receptor near phrenic motoneurons (2) . BDNF-TrkB interactions may strengthen glutamatergic synapses onto phrenic motoneurons. In support of this, McGuire and colleagues (23) demonstrated that NMDA receptor activation near phrenic motoneurons is necessary for LTF. In their study, McGuire and colleagues administered the noncompetitive NMDA receptor-channel blocker MK-801 spinally near phrenic motoneurons before rats were exposed to intermittent hypoxia to block phrenic LTF.
We have recently described a new model of phrenic motor plasticity, where spinal A2a receptor activation elicits a persistent increase in phrenic motor output in anesthetized rats by strengthening spinal synaptic pathways to phrenic motoneurons (11, 13) . When administered systemically, A2a receptor agonists also increase tidal volume in awake spinally injured rats (13) . Although adenosine has also been demonstrated to stimulate ventilation via carotid body A2a receptor activation, we propose that at least some of the facilitation observed in awake rats is attributed to spinal A2a receptor activation near phrenic motoneurons. Unlike phrenic LTF, new synthesis of BDNF near phrenic motoneurons is not necessary for A2a receptor-mediated phrenic motor facilitation. However, similar to phrenic LTF, our model of phrenic motor plasticity requires activation of TrkB protein. We propose that A2a receptor agonists transactivate TrkB protein near phrenic motoneurons. Transactivation occurs when a G protein-coupled receptor ligand indirectly activates a second receptor without the need for the second receptor's ligand (18) . The aim of this study was to investigate whether NMDA receptor activation also was necessary for the initiation and/or maintenance of A2a-induced phrenic motor facilitation. To this end, we hypothesized that the NMDA receptor channel blocker MK-801 would block A2a receptor-mediated phrenic motor facilitation.
METHODS

Animals.
All experiments were conducted on adult (3-5 mo old) male Sprague-Dawley rats (Harlan colony 217; Harlan, Indianapolis, IN; 336 -410 g; n ϭ 73). In the first series of experiments, we investigated the dose-response relationships for CGS-21680, an A2a receptor agonist, and MK-801, an NMDA receptor-channel blocker, on the magnitude of A2a receptor-mediated phrenic motor facilitation. CGS-21680 at increasing concentrations (0.5, 5.0, 50.0, and 500 M; n ϭ 6 rats for 0.5, 5.0, and 500 M doses, and n ϭ 8 rats for the 50.0 M dose) was injected intrathecally to anesthetized rats. In a separate series of rats, MK-801 at increasing concentrations (0.1, 1.0, 10.0, and 100 M; n ϭ 6 rats for 0.1, 1.0, and 100 M doses, and n ϭ 8 rats for the 10.0 M dose) was injected intrathecally 30 min before CGS-21680 administration. Given that NMDA receptors contribute to fast synaptic transmission to phrenic motoneurons and, therefore, that MK-801 could decrease baseline phrenic nerve activity (6) , the aim of the initial experiments was to determine the minimal dose of MK-801 necessary to abolish A2a receptor-mediated phrenic plasticity with little or no effect on baseline phrenic motor output.
In the second series of experiments, we administered MK-801 at 60 min (n ϭ 6) after intrathecal injection of CGS-21680 to assess whether 1) NMDA receptor activation contributed to facilitation beyond 60 min post-CGS-21680, and 2) NMDA receptor activation was necessary for the maintenance of A2a receptor-mediated phrenic motor plasticity. An additional 15 rats were included as DMSO only (n ϭ 6), MK-801 only (n ϭ 5), and CGS-21680 ϩ DMSO at 60 min post-CGS-21680 (n ϭ 4) time controls. The Institutional Animal Care and Use Committee at the University of Pennsylvania, Philadelphia approved all experimental procedures.
Instrumentation. Phrenic nerve activity was recorded in anesthetized rats before and after intrathecal drug administration. At least 1 wk elapsed between animal delivery to the animal housing facility and use in the terminal electrophysiological study. Rats were initially anesthetized in a small chamber with isoflurane in oxygen. The lateral tail vein was cannulated to administer fluids (4 ml ⅐ kg Ϫ1 ⅐ h Ϫ1 iv, 50:50 mixture of lactated Ringer and 6% hetastarch) throughout the experiment. The trachea was surgically exposed at the midcervical level and cannulated to permit mechanical ventilation (pump frequency 60 min Ϫ1 ; tidal volume 7 ml/kg; Rodent Ventilator model 7025; Ugo Basile, Comerio, Italy). After instigating mechanical ventilation, both cervical vagi were transected to prevent entrainment of phrenic nerve activity to the ventilator cycle. The femoral artery was cannulated to enable direct arterial blood pressure monitoring (model P122, Grass Telefactor, West Warrick, RI) and sampling of arterial blood for pH and blood gas analysis (iSTAT, Heska, Loveland, CO). End-tidal PCO2 (PETCO 2 ) was measured continuously using a mainstream sensor attached to the expiratory limb of the breathing circuit and within 5 cm of the patient Y-piece connector (Capnoguard, Novametrix Medical Systems, Wallingford, CT). Rats were then positioned in a stereotaxic head frame. The left phrenic nerve was isolated in the neck via a dorsal approach, cut distally, and the proximal stump was desheathed and placed over bipolar silver electrodes. In the five rats that received MK-801 alone, the left hypoglossal nerve also was isolated as a control for supraspinal spread of the NMDA receptor antagonist. In these rats, phrenic and hypoglossal motor output was recorded before and after MK-801 administration. In preliminary studies, hypoglossal and phrenic nerve activity was recorded before and after intravenous injection of MK-801 (n ϭ 3; 0.2 mg/kg). Both hypoglossal and phrenic nerve activity decreased after systemic MK-801 administration, which supports the use of changes in hypoglossal motor activity as a control for supraspinal effects of MK-801. Hypoglossal motor output was not recorded in the other groups because we have previously demonstrated that spinal administration of 50 M CGS-21680 does not alter supraspinal respiratory motor output (13) .
The first and second cervical vertebral laminae were exposed for intrathecal cannulation. A silicon cannula (PE-10) attached to a Hamilton syringe and filled with the specified drug or vehicle solution was advanced through a durotomy between the C1 and C2 vertebral bodies until the tip of the cannula rested over the C4 spinal segment. Total surgical preparation required 45-60 min per rat. After cannulation, rats were converted to urethane anesthesia (1.8 g/kg iv) while isoflurane was slowly discontinued. When conversion was complete, rats were neuromuscularly paralyzed with pancuronium bromide (2 mg/kg iv). Following conversion to urethane anesthesia, at least 1 h elapsed before protocols began. Phrenic nerve activity was recorded continuously, amplified (gain, 10,000; A-M Systems, Everett, WA), band pass-filtered (100 Hz to 10 kHz), rectified, and moving averaged (CWE 821 filter; Paynter, Ardmore, PA; time constant, 50 ms), digitized (MK1401, CED, Cambridge, UK), and recorded (Spike 2, CED, Cambridge, UK).
Standardizing baseline phrenic motor output. In an attempt to standardize baseline motor activity between individuals, baseline phrenic burst amplitude was established at 3 mmHg PET CO 2 above the apneic threshold to CO 2 (12) . To achieve this, the ventilator cycle frequency was increased until phrenic nerve activity ceased. After 2 min of fictive apnea had elapsed, ventilator frequency was slowly decreased, and PETCO 2 allowed to slowly increase, until rhythmic phrenic nerve activity resumed. The PET CO 2 at the onset of phrenic nerve activity was recorded as the apneic threshold to CO 2.
Phrenic nerve activity was recorded for 40 min during baseline conditions and for 120 min following intrathecal drug administration. Arterial blood samples were collected during baseline conditions and at 60 and 120 min after intrathecal drug administration. Arterial PCO 2 (PaCO 2 ) was controlled by making small adjustments to the ventilator cycle frequency. Animals were included in the final analysis only if arterial PO2 (PaO 2 ) during the entire experiment remained above 150 mmHg, and if Pa CO 2 was within 1.5 mmHg of the baseline value during postinjection measurement periods.
Intrathecal drug administration. A dose-response curve for the effects of intrathecal CGS-21680 on phrenic motor output has not been published. Thus our first requirement was to determine an efficacious dose of CGS-21680 that could be used in the antagonist studies. CGS-21680 was dissolved in 10% DMSO (balance normal saline) and administered intrathecally over the C4 spinal segment in five different concentrations (0, 0.5, 5.0, 50.0, and 500 M). The volume of CGS-21680 was standardized to 10 l, injected three times over a 2-min period with 5-min separating each dose. Preliminary experiments suggest that intermittent administration elicits larger facilitation than an equivalent massed dose.
After the optimal dose of CGS-21680 had been determined, we proceeded to dose-response experiments using MK-801 as a noncompetitive channel blocker of the NMDA receptor. MK-801 was dissolved in 10% DMSO (balance normal saline) and administered intrathecally at increasing concentrations (0, 0.1, 1.0, 10.0, and 100 M) 30 min before intrathecal injection of CGS-21680. In five rats, the apneic threshold to PETCO 2 was remeasured after administration of MK-801 (in the MK-801 only group) to ensure that the antagonist did not alter the apneic threshold. The baseline arterial blood gas sample was collected after MK-801 administration and immediately before CGS-21680 injection. The effects of intrathecal administration of 10% DMSO solution alone and MK-801 alone on phrenic nerve activity were assessed in separate control groups.
Statistical analysis. Peak phrenic burst amplitude and burst frequency ("fictive" respiratory frequency) were measured offline over a 30-s period immediately before blood samples. Statistical inferences were based on a two-way ANOVA with a repeated-measures design [factors: time (repeated measures) and treatment], with individual comparisons made using Bonferroni's post hoc test when indicated.
Differences were considered significant if P Ͻ 0.05. All values are expressed as means Ϯ SE.
RESULTS
The dose-response curve for CGS-21680. The measurements of rectal temperature, arterial blood pH, Pa CO 2 , Pa O 2 , mean arterial pressure, and the PET CO 2 at apneic threshold for rats receiving 0.5, 5.0, and 500 M of CGS-21680 are not reported here because they were not statistically different from each other or the minimally effective concentration of 50 M CGS-21680. Instead, we present the data for these variables from the 50 M CGS-21680 group as representative measurements in Table 1 . Mean arterial pressure was lower at 120 min post-drug administration compared with baseline values, but this effect was similar across all concentrations, in each dose-response study, and the DMSO time controls (Table 1 ; P Ͻ 0.05).
Intrathecal administration of CGS-21680 increased phrenic inspiratory burst amplitude above baseline values in a dosedependent manner (Fig. 1A) . The lowest and most effective concentration studied was 50 M CGS-21680 (126 Ϯ 16%, above baseline, P Ͻ 0.05) (Fig. 1A) , and this concentration was used in the dose-response studies involving MK-801 administration. Ten percent DMSO (balance normal saline) alone did not alter phrenic burst amplitude (4 Ϯ 5% above baseline at 120 min postdrug), demonstrating that the vehicle was unlikely to contribute to changes in phrenic nerve activity after CGS-21680 administration (Fig. 1A) . Phrenic burst frequency (fictive respiratory rate) did not change after vehicle or A2a receptor agonist administration (at any concentration). Frequency data for vehicle and 50 M CGS-21680 are presented in Table 1 . Consequently, phrenic minute activity (the product of inspiratory burst amplitude and fictive respiratory frequency) mirrored the change in phrenic burst amplitude after CGS-21680 administration (0.5 M CGS-21680: 7 Ϯ 7%; 5.0 M CGS-21680: 40 Ϯ 5%; 50 M CGS-21680: 130 Ϯ 15%; 500 M CGS-21680: 115 Ϯ 12%, above baseline, P Ͻ 0.05).
Effects of pretreatment with MK-801 on A2a receptormediated phrenic motor facilitation. As described above, a set of representative measurements for rectal temperature, arterial blood pH, Pa CO 2 , Pa O 2 , mean arterial pressure, and the PET CO 2 at apneic threshold is presented in Table 1 for rats receiving 10 M MK-801 and 50 M CGS-21680. Complete data sets for all the groups in the dose-response study are not reported for the same reason as described above.
Intrathecal injection of MK-801 at concentrations between 0.1 and 10 M did not alter baseline phrenic minute activity for the 30-min recording period prior to CGS-21680 administration (0.1 M MK-801: 1 Ϯ 7%; 1.0 M MK-801: 5 Ϯ 5%; 10 M MK-801: Ϫ6 Ϯ 10). However, at 100 M MK-801, phrenic burst amplitude decreased (Ϫ18 Ϯ 7%; below baseline, P Ͻ 0.05) and this effect persisted for at least 30 min post-MK-801. The reduction in minute activity was primarily due to a decrease in phrenic burst amplitude (change in frequency: 2 Ϯ 6%; change in phrenic burst amplitude: Ϫ21 Ϯ 5%; below baseline, P Ͻ 0.05).
Pretreatment with MK-801 dose-dependently decreased the magnitude of A2a receptor-mediated phrenic motor facilitation (Fig. 1A) . The most effective concentration of MK-801 with the least variability and the least effect on baseline phrenic motor output was 10 M (Fig. 1A) . Again, fictive respiratory rate did not change after CGS-21680 administration. Representative frequency data for 10 M MK-801 and 50 M CGS-21680 are presented in Table 1 . Again, phrenic minute activity mirrored the change in phrenic burst amplitude after Two additional rats were added to each of the 50 M CGS-21680 alone and 10 M MK-801 ϩ 50 M CGS-21680 groups to increase the sample size to eight. Thirty, 60-, 90-, and 120-min phrenic neurogram data for these treatment groups and the control groups MK-801 alone and 10% DMSO alone are presented in Fig. 1, B and C. A2a receptor activation elicited a progressive increase in phrenic burst amplitude that was significantly higher than vehicle at 60, 90, and 120 min after drug administration (Fig. 1, B and C) . Pretreatment with MK-801 abolished all A2a receptor-mediated facilitation (Fig.  1, B and C) .
Hypoglossal motor output was recorded from the five rats that received intrathecal 10 M MK-801 alone as a control for supraspinal spread of the antagonist. MK-801 did not alter baseline hypoglossal minute activity for the 120-min recording period after drug administration (10 M MK-801: 15 Ϯ 10%, above baseline). The apneic threshold to PET CO 2 also was not different before and after MK-801 administration in this control group (before MK-801: 39 Ϯ 2 mmHg; after MK-801: 40 Ϯ 1 mmHg).
Effects of MK-801 on A2a receptor-mediated phrenic motor facilitation when administered at 60 min post-CGS-21680.
Having established that pretreatment with MK-801 blocks A2a receptor-mediated phrenic motor facilitation, we now investigated whether delayed NMDA receptor blockade, at 60 min post-CGS-21680 administration, would have similar effects. Six rats received intrathecal 10 M MK-801 at 5 min after collection of the 60-min arterial blood sample from rats that had received intrathecal 50 M CGS-21680. Delayed administration of MK-801 prevented further increases in phrenic burst amplitude but did not decrease phrenic burst amplitude or fictive respiratory frequency. Thus, by 120 min post-CGS-21680 (60 min after MK-801), the magnitude of A2a receptormediated phrenic motor facilitation was similar to pre-MK-801 values and the magnitude of phrenic motor plasticity in the CGS-21680 alone group was significantly higher than all other groups (Fig. 2, A and B) . As a vehicle control, four rats received 10% DMSO intrathecally at 65 min post-CGS-21680. The magnitude of phrenic motor facilitation at 120 min post-CGS-21680 was not different from rats that only received CGS-21680 (CGS-21680 alone: 126 Ϯ 16%; CGS-21680 ϩ DMSO: 140 Ϯ 25%, above baseline, n ϭ 4).
DISCUSSION
Here, we demonstrate that spinal administration of the NMDA receptor-channel blocker MK-801 blocked A2a receptor-mediated phrenic motor facilitation at concentrations that did not change baseline phrenic nerve activity. However, when MK-801 was administered at 60 min after the A2a receptor agonist, further phrenic motor facilitation ceased, and the magnitude of preexisting facilitation was maintained. Thus we propose that spinal NMDA receptor activation is necessary for de novo A2a receptor-mediated phrenic motor facilitation but not the maintenance of said plasticity.
Methodological considerations. NMDA receptors contribute to fast synaptic transmission of inspiratory drive to phrenic motoneurons and plasticity of phrenic motor output (1, 5, 6, , and the DMSO control (n ϭ 6). C: representative phrenic neurograms for rats in the groups described above. 23 ). If the NMDA receptor channels that transmit inspiratory drive were the same receptors that regulate phrenic motor plasticity, we would expect concurrent reductions in baseline phrenic nerve activity and the magnitude of phrenic motor facilitation when using MK-801. However, this dual effect of MK-801 was only observed in rats that received the highest concentration of 100 M MK-801. We did not observe any change in baseline phrenic nerve activity during, or for 30 min after intrathecal injection of lower concentrations, even though 1.0 and 10 M MK-801 was sufficient to inhibit A2a receptormediated phrenic motor plasticity. Our data are consistent with a similar study in which MK-801 was microinjected near phrenic motoneurons before exposing rats to intermittent hypoxia (23) . McGuire and colleagues administered three different doses of MK-801 (10 M, 300 M, and 5 mM MK-801), all of which blocked phrenic LTF. However, baseline phrenic nerve activity also decreased in a dose-dependent manner, with baseline activity decreasing by one-third at 10 M MK-801 and completely abolished at 5 mM of the antagonist. Although we used a similar concentration and volume of MK-801 (10 M and 30 l) in the present study, we did not observe a change in phrenic nerve activity after MK-801 administration. We believe this difference between studies reflects the different methods of drug injection: intrathecal vs. microinjection. It is plausible that the concentration of MK-801 near phrenic motoneurons in our study was less than 10 M due to dilution. Also, microinjection is more invasive and could damage motoneurons or their afferent connections.
The reason for the dual effects of MK-801 on phrenic nerve activity and plasticity separated by dose is unknown. It is plausible that the lower concentrations of MK-801 may require more time than higher concentrations to penetrate the spinal cord and block phrenic NMDA receptors. If this is true, then baseline phrenic motoneuron activity may be inhibited later in the protocol and interpreting the effects of NMDA receptor blockade on phrenic motor plasticity would be more difficult. To address this potential issue, we investigated the timedependent effects of 10 M MK-801 by recording phrenic nerve activity for at least 120 min postinjection. We did not observe any significant change in phrenic nerve activity for the duration of the recordings, suggesting that insufficient diffusion time was not a cause for this lack of an effect.
As an alternative explanation, the dual effects of MK-801 on phrenic nerve activity and plasticity separated by MK-801 concentration may reflect diversity in the subunit composition and/or spatial distribution of spinal NMDA receptor populations (17) . For example, NMDA receptors that contribute to fast synaptic transmission are likely to be restricted to the postsynaptic density (17) . On the other hand, NMDA receptors that regulate plasticity are predicted to be peri-or extrasynaptic (17) . It has been proposed that NMDA receptor subunit expression and receptor-channel composition varies between synaptic and extrasynaptic sites and that a heterogeneous population of NMDA receptor channels would exhibit a heterogeneous pharmacological phenotype (17) . If this is true for NMDA receptors near phrenic motoneurons, our data would suggest that low concentrations of MK-801 were more efficacious at the NMDA receptors responsible for phrenic motor plasticity than those involved in fast synaptic transmission of respiratory motor drive.
NMDA receptors contribute to the neural control of breathing at multiple levels within the central nervous system. For example, MK-801 has been demonstrated to prolong inspiratory time and elicit an apneustic breathing pattern (9, 26) , and diminish the hypoxic ventilatory response at the level of the nucleus tractus solitarius (33) . Thus MK-801 could decrease the magnitude of A2a receptor-mediated phrenic motor facilitation at supraspinal levels. We believe supraspinal mechanisms are not involved in the effects of spinal administration of 10 M MK-801 on phrenic nerve activity because fictive respiratory rate, hypoglossal motor activity, and the apneic threshold to CO 2 was not different before and after MK-801 administration. McGuire and colleagues (23) also did not observe an effect of MK-801 injection on the apneic threshold to CO 2 . In a previous study, using similar controls and indexes, we also demonstrated that intrathecal injection of 50 M CGS-21680 elicited phrenic motor facilitation primarily via spinal mechanisms (13) .
Possible mechanisms. A2a receptor-mediated phrenic motor facilitation requires new synthesis and activation of spinal TrkB protein but does not require new synthesis of BDNF, suggesting that TrkB activation occurs via a ligand-independent process. This is distinct from hypoxia-induced phrenic LTF where new synthesis of BDNF and subsequent TrkB activation near phrenic motoneurons is necessary for motor facilitation (2) . In our model, we propose that TrkB is activated by a process known as transactivation (13) . The term transactivation describes a process whereby activation of a G proteincoupled receptor (in this case the A2a receptor) activates a second receptor (i.e., TrkB) without a need for the second receptor's ligand (namely, BDNF). Thus both A2a receptor- Synaptic plasticity can strengthen spinal pathways to phrenic motoneurons (10) , thereby contributing to a persistent increase in phrenic burst amplitude. In an earlier study, we recorded evoked phrenic potentials before and at 120 min after intrathecal administration of CGS-21680 (13) . Phrenic evoked potential amplitude increased after spinal A2a receptor activation, suggesting that the A2a receptor ligand strengthened spinal synaptic pathways to phrenic motoneurons. A strong positive correlation existed between A2a receptor-mediated evoked potential facilitation and phrenic motor facilitation, suggesting that strengthened spinal synaptic pathways (vs. increased respiratory premotor drive) underlie this model of phrenic motor plasticity.
The neurotransmitter glutamate is primarily responsible for transmitting excitatory drive from bulbospinal premotor neurons to phrenic motoneurons (22) . Glutamate excites phrenic motoneurons via the AMPA receptor alone in neonatal rats (21) and both the AMPA and NMDA receptor in adult rats (6) . In general, AMPA receptors are considered to be an expresser of synaptic plasticity (i.e., as a potentiated ion channel) and not as a regulator of synaptic strength. In contrast, NMDA receptors can have both roles. Indeed, NMDA receptor activation has been implicated in various models of synaptic plasticity (4, 34, 38) , including hypoxia-induced phrenic LTF (23) , and the crossed phrenic phenomenon (1). Our present study provides further evidence for a role of NMDA receptor activation in strengthening synaptic pathways to phrenic motoneurons and the initiation of phrenic motor plasticity.
Three gene families (NR1, NR2, and NR3) encode three classes of NMDA receptor subunits (7) . Functional NMDA receptors are tetramers composed of two essential NR1 subunits and two NR2 subunits. The NR2 subunit conveys the diverse array of electrophysiological and pharmacological properties of NMDA receptors. The COOH termini of NMDA receptor subunits are substrates for posttranslational modifications such as phosphorylation (19) . Phosphorylation can regulate channel properties of NMDA receptors and ultimately increase synaptic strength. The NR1 subunit has been located histologically on phrenic motoneurons (37) . Although anatomic data are lacking, at least one type of NR2 subunit is likely to be present on (or near) phrenic motoneurons because NR2 protein is necessary for NMDA receptor function and NR2 subunit antagonism decreases phrenic motor output (5, 6).
The cellular processes connecting spinal A2a receptor activation to NMDA-dependent phrenic motor facilitation remain unknown. NMDA receptor activation may occur upstream, downstream, or even parallel to A2a receptor-mediated TrkB receptor activation. Further studies using histochemical and Western analyses will be required to elucidate these relationships. However, based on other models of memory and synaptic plasticity in the literature, we can speculate that A2a-induced TrkB activation may elicit synaptic plasticity via downstream NMDA receptor activation (41) . The identity of the non-NMDA receptor mechanism(s) maintaining A2a receptor-mediated phrenic motor facilitation remains unknown. Given that MK-801 blocked all facilitation for 120 min after CGS-21680 administration, it is plausible that NMDA receptor activity is required to initiate these maintenance mechanisms.
In preliminary experiments, we have recorded phrenic motor facilitation for up to 3 h after A2a receptor agonist administration. In other unpublished experiments (Golder, 2009 ), A2a-induced ventilatory facilitation can persist for up to 24 h after drug administration. The role of NMDA receptors in maintaining facilitation at these extreme time points remains unknown.
Significance. Respiratory failure is the leading cause of mortality in people with acute and chronic cervical SCI (40) , and more than 50% of spinal injuries involve cervical spinal segments (15) . Thus therapeutic approaches that improve breathing could significantly enhance quality of life and life expectancy in a large population of people. Recently, theophylline, a broad-spectrum adenosinergic receptor antagonist, has been investigated as a pharmacological tool to improve breathing after SCI. In animal models, theophylline increases phrenic motor output and diaphragm activation after cervical SCI (28, 30 -32) . The mechanisms responsible for these effects are unknown. In one case report (3), aminophylline increased diaphragm EMG activity in a C5-C6 spinally injured ventilator-dependent person. The patient was eventually weaned from ventilatory support. Theophylline may be limited in usefulness to the immediate postinjury period: when theophylline was administered to rats at 2 mo after cervical SCI, respiratory motor output decreased (29) . To our knowledge, there are no pharmacological approaches that specifically improve breathing in the chronically injured population. A2a receptor agonists may provide a valuable strategy for improving breathing in the chronic spinally injured population.
